Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen (NASDAQ:BIIB).
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical (NASDAQ:BMRN) and the rest of the therapeutics stocks fared in Q2.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Shares of biotech company Biogen (NASDAQ:BIIB)
fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the stock to perform in line with the broader market, lacking a significant catalyst for a major move in either direction. The reiterated neutral stance comes with no change to the price target. The market's negative reaction may indicate that some investors were anticipating a more positive outlook or an upgrade for the biotechnology company.
Wall Street kicked off September on shaky ground as rising bond yields pressured tech stocks and legal turmoil over Trump’s tariffs added fresh uncertainty. Meanwhile, investors brace for Friday’s key jobs report that could steer the Fed's next move.
Shares of biotech company Biogen (NASDAQ:BIIB)
jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their Alzheimer's drug, Leqembi, for maintenance dosing.
Wall Street stumbled on Tuesday, with broad losses by midday in New York as investors turned risk-off amid mounting concerns over lofty valuations, seasonal headwinds and fiscal strains.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.
